These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19969409)

  • 21. Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest.
    Fraser IS; Jensen J; Schaefers M; Mellinger U; Parke S; Serrani M
    Contraception; 2012 Aug; 86(2):96-101. PubMed ID: 22240178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estradiol valerate/dienogest: a novel oral contraceptive.
    Whalen KL; Rose R
    Ann Pharmacother; 2011 Oct; 45(10):1256-61. PubMed ID: 21917554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.
    Raps M; Rosendaal F; Ballieux B; Rosing J; Thomassen S; Helmerhorst F; van Vliet H
    J Thromb Haemost; 2013 May; 11(5):855-61. PubMed ID: 23410231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Palombo-Kinne E; Kuhl H
    Contraception; 2011 Aug; 84(2):133-43. PubMed ID: 21757054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
    Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
    Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis in the treatment of heavy menstrual bleeding in Spain.
    Calaf J; Lete I; Canals I; Crespo C; Espinós B; Cristóbal I
    Eur J Obstet Gynecol Reprod Biol; 2015 Jan; 184():24-31. PubMed ID: 25462215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contraception containing estradiol valerate and dienogest--advantages, adherence and user satisfaction.
    Graziottin A
    Minerva Ginecol; 2014 Oct; 66(5):479-95. PubMed ID: 25245997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
    Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
    Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
    Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding.
    Wasiak R; Filonenko A; Vanness DJ; Law A; Jeddi M; Wittrup-Jensen KU; Stull DE; Siak S; Jensen JT
    J Womens Health (Larchmt); 2013 Apr; 22(4):378-84. PubMed ID: 23586801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
    Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
    Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest.
    Wiegratz I; Mittmann K; Dietrich H; Zimmermann T; Kuhl H
    Fertil Steril; 2006 Jun; 85(6):1812-9. PubMed ID: 16759929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in the Czech Republic.
    Golbs S; Domhardt R; Presl J; Ganev M; Wisser KH; Zimmermann T
    Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):689-96. PubMed ID: 12616963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unintended pregnancy rates differ according to combined oral contraceptive - results from the INAS-SCORE study.
    Barnett C; Dinger J; Minh TD; Heinemann K
    Eur J Contracept Reprod Health Care; 2019 Aug; 24(4):247-250. PubMed ID: 31204884
    [No Abstract]   [Full Text] [Related]  

  • 35. What role for Qlaira in contraception?
    Drug Ther Bull; 2010 Sep; 48(9):102-5. PubMed ID: 20810709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Kuhl H
    Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of estradiol valerate and dienogest on quality of life and sexual function according to age.
    Di Carlo C; Gargano V; De Rosa N; Tommaselli GA; Sparice S; Nappi C
    Gynecol Endocrinol; 2014; 30(12):925-8. PubMed ID: 25366390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study.
    Endrikat J; Parke S; Trummer D; Serrani M; Duijkers I; Klipping C
    Contraception; 2013 Feb; 87(2):227-34. PubMed ID: 22995539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women.
    Endrikat J; Lange E; Kunz M; Schmidt W; Graeser T
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):229-39. PubMed ID: 17763261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.